Studies reveal that the air inside our homes is more polluted than the air outdoors, and a portion of these toxins come from ...

The rising prevalence of respiratory diseases and technological advancements drive significant market growth.Pune, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Aerosol Drug Delivery Devices Market Size & Growth ...

becoming the first inhaled product with a novel mechanism of action available for the maintenance treatment of COPD in more than 20 years, and launched a few weeks later. Third-quarter sales of $6 ...

Pope Francis was resting Saturday after an alarming setback in his two-week recovery from double pneumonia: Doctors had to put him on noninvasive mechanical ventilation following a ...

The global Cystic Fibrosis Market is valued at $10.4 billion in 2023 and is projected to reach $55.4 billion by 2032, ...

If your cold symptoms won't quit, you may have something else. Doctors explain what it could mean if you've got a lingering ...

ICER assessed GSK's COPD inhalers, Trelegy Ellipta and Breo Ellipta, for Medicare price negotiations, highlighting their once-daily dosing and comparable net health benefits.

Patients with COPD had better inhaler adherence when invited to enroll in a program that lowers cost sharing for maintenance inhalers and offers medication management services, according to results ...